Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Perturbagen Concentration | Perturbagen Conc Unit | Biological Replicate ID | Relative Cell Count | Normalized Growth Rate Inhibition Value | Nominal Division Rate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MDA-MB-157 | TNBC | Basal B | Imatinib | ABL/KIT/PDGFR | nRTK | 0.181 | uM | 7498.091 | 1.0447 | 1.0779 | 1.1445 | |
| MDA-MB-157 | TNBC | Basal B | Imatinib | ABL/KIT/PDGFR | nRTK | 0.904 | uM | 7498.091 | 1.0652 | 1.1135 | 1.1445 | |
| MDA-MB-157 | TNBC | Basal B | Imatinib | ABL/KIT/PDGFR | nRTK | 4.52 | uM | 7498.091 | 0.9953 | 0.9918 | 1.1445 | |
| MDA-MB-157 | TNBC | Basal B | Imatinib | ABL/KIT/PDGFR | nRTK | 22.6 | uM | 7498.091 | 0.5905 | 0.2621 | 1.1445 | |
| MDA-MB-157 | TNBC | Basal B | Imatinib | ABL/KIT/PDGFR | nRTK | 113 | uM | 7498.091 | 0.0105 | -0.9626 | 1.1445 | |
| MDA-MB-157 | TNBC | Basal B | Imatinib | ABL/KIT/PDGFR | nRTK | 565 | uM | 7498.091 | 0.0075 | -0.9722 | 1.1445 | |
| MDA-MB-175-VII | HR+ | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 0.00145 | uM | 7499.09 | 0.9651 | 0.9246 | 0.9238 | |
| MDA-MB-175-VII | HR+ | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 0.00723 | uM | 7499.09 | 0.9867 | 0.9712 | 0.9238 | |
| MDA-MB-175-VII | HR+ | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 0.0362 | uM | 7499.09 | 0.9428 | 0.8764 | 0.9238 | |
| MDA-MB-175-VII | HR+ | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 0.181 | uM | 7499.09 | 0.8949 | 0.7734 | 0.9238 | |
| MDA-MB-175-VII | HR+ | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 0.904 | uM | 7499.09 | 0.9795 | 0.9556 | 0.9238 | |
| MDA-MB-175-VII | HR+ | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 4.52 | uM | 7499.09 | 0.8267 | 0.6275 | 0.9238 | |
| MDA-MB-175-VII | HR+ | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 22.6 | uM | 7499.09 | 0.3744 | -0.3095 | 0.9238 | |
| MDA-MB-175-VII | HR+ | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 113 | uM | 7499.09 | 0.0009 | -0.9990 | 0.9238 | |
| MDA-MB-175-VII | HR+ | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 565 | uM | 7499.09 | 0.0013 | -0.9985 | 0.9238 | |
| MDA-MB-175-VII | HR+ | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 0.00145 | uM | 7500.091 | 1.0375 | 1.1216 | 0.6237 | |
| MDA-MB-175-VII | HR+ | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 0.00723 | uM | 7500.091 | 1.0786 | 1.2580 | 0.6237 | |
| MDA-MB-175-VII | HR+ | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 0.0362 | uM | 7500.091 | 0.9197 | 0.7488 | 0.6237 | |
| MDA-MB-175-VII | HR+ | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 0.181 | uM | 7500.091 | 1.0022 | 1.0071 | 0.6237 | |
| MDA-MB-175-VII | HR+ | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 0.904 | uM | 7500.091 | 1.0611 | 1.1994 | 0.6237 | |
| MDA-MB-175-VII | HR+ | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 4.52 | uM | 7500.091 | 0.9955 | 0.9855 | 0.6237 | |
| MDA-MB-175-VII | HR+ | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 22.6 | uM | 7500.091 | 0.5566 | -0.2183 | 0.6237 | |
| MDA-MB-175-VII | HR+ | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 113 | uM | 7500.091 | 0.0242 | -0.9949 | 0.6237 | |
| MDA-MB-175-VII | HR+ | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 565 | uM | 7500.091 | 0.0072 | -0.9993 | 0.6237 | |
| MDA-MB-231 | TNBC | Basal B | Imatinib | ABL/KIT/PDGFR | nRTK | 0.00145 | uM | 7504.091 | 0.9134 | 0.9111 | 1.9941 |